Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208819 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT00208819 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 50 participants.
The verdict
NCT00208819, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG quetiapine
- DRUG divalproex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208819
The ClinicalTrials.gov registry entry for NCT00208819 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which risperidone is the first listed.
NCT00208819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208819 about?
NCT00208819 is a clinical study titled "A Comparison of Two Standard Therapies in the Management of Dementia With Agitation". The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.
What is the current status of trial NCT00208819?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2003-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00208819?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), quetiapine (DRUG), divalproex (DRUG).
Who is sponsoring clinical trial NCT00208819?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.